PIVKA-II Is the Best Prognostic Predictor in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation Therapy
Shunsuke Takahashi(Kanagawa Dental University), Kazuomi Ueshima(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Yasunori Minami, Tatsuo Inoue, Tomoyuki Nagai(Tohoku University), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Chie Tatsumi(Kindai University), Taisuke Ueda(Kindai University), Hobyung Chung(Kindai University)
Cited by 25
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k